Biocon (NSE:BIOCON) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BIOCON Biocon Ltd NSE:BIOCON
87 GF Score
Price ₹395.00
GF Value ₹325.36
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Biocon Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

NSE:BIOCON
87GF Score
Biocon Ltd NSE:BIOCON
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biocon (NSE:BIOCON) Overvalued in 2026?

Based on GuruFocus' analysis, Biocon stock appears to be overvalued. The current stock price of ₹395.00 is trading 21.4% above its estimated GF Value™ of ₹325.36. GuruFocus considers Biocon to be Modestly Overvalued.

Key valuation signals for NSE:BIOCON:

  • Interest Received:
  • GF Value™: ₹325.36 vs. price of ₹395.00 (21.4% above fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the NSE:BIOCON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biocon Business Description

Other Exchanges 532523:India
Address 20th KM, Hosur Road, Electronics City, Bengaluru, KA, IND, 560100
Biocon Ltd is an Indian biopharmaceutical company that develops and manufactures generic active pharmaceutical ingredients, formulations, and biosimilar medicines. It operates through three main segments: Generics, which supplies small-molecule APIs and finished dosages; Biosimilars, its largest revenue contributor, focused on treatments for diabetes, oncology, and autoimmune and inflammatory conditions; and Syngene, its research and manufacturing services arm serving global pharmaceutical and biotech clients. The company sells in India and internationally, with significant business in the United States, Europe, and emerging markets, and it has expanded its biosimilars presence in developed markets through partnerships and regulatory approvals. Revenue comes from product sales of APIs, generics, and biosimilars, plus contract research and manufacturing services. Biocon is headquartered in Bengaluru, India, and is listed on Indian stock exchanges.
87GF Score

Get the complete analysis for NSE:BIOCON

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹395.00
Price
₹325.36
GF Value